Experience with corneal collagen cross-linking finds new indication, safety criteria

Article

Increasing clinical experience with corneal collagen cross-linking using combined topical riboflavin application and ultraviolet-A (UVA) irradiation indicates this simple, nonsurgical intervention may be an effective treatment for keratoconus and iatrogenic keratectasia. However, its safety may depend on respecting a minimum corneal thickness threshold of 400 microns as a criterion for candidate selection, said Theo Seiler, MD, at the World Ophthalmology Congress.

Increasing clinical experience with corneal collagen cross-linking using combined topical riboflavin application and ultraviolet-A (UVA) irradiation indicates this simple, nonsurgical intervention may be an effective treatment for keratoconus and iatrogenic keratectasia. However, its safety may depend on respecting a minimum corneal thickness threshold of 400 microns as a criterion for candidate selection, said Theo Seiler, MD, at the World Ophthalmology Congress.

Dr. Seiler of the Institute for Refractive and Ophthalmic Surgery, Switzerland, explained Wednesday that the procedure aims to increase the stiffness of the cornea and its mechanical and biochemical resistance by inducing additional chemical bonds within the connective tissue. Initial preclinical experiments in which animal eyes underwent corneal abrasion, followed by 30 minutes of application of 0.1% riboflavin and irradiation with a UVA light source (365-nm, 3 mW/cm2) demonstrated that corneal biomechanical strength increased 1.5-fold.

The technique was first performed clinically in patients with keratoconus, and those studies showed it could convert progressive disease into forme fruste keratoconus without causing any complications or evidence of toxicity to the cornea, lens or iris. More recent experience in eyes with iatrogenic keratectasia has also produced exciting results, as the procedure was associated with a reduction in keratometry readings rather than just stabilization.

However, in an eye with iatrogenic kerectasis, an adverse endothelial reaction occurred as the first complication of the cross-linking procedure. That experience led to further research on keratocyte cytotoxicity of the riboflavin/UVA treatment and the recommendation for the corneal thickness rule.

"Studies in cell cultures and animal eyes show there is a very sharp endothelial damage threshold for this treatment at an irradiance level of 0.3 mW/cm2, and while the intensity of radiation delivered decreases with increasing corneal depth, there appears to be a risk for endothelial damage in thinner corneas where the endothelium is closer to the surface," said Dr. Seiler.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.